Ensysce Biosciences has upside of more than 250%, based on the $29.50 per share valuation of Zacks Small-Cap Research (Zacks SCR). The company is developing treatments for severe pain relief that have the power of opioids but do not carry the risk of abuse. Its products could help to put…